1. Structure-guided design of pure orthosteric inhibitors of αIIbβ3 that prevent thrombosis but preserve hemostasis
- Author
-
M. Amin Arnaout, I-Shing Yu, Shu-Wha Lin, Vincent Hayes, Johannes van Agthoven, Brian D. Adair, Hyun Sook Ahn, Mortimer Poncz, José Luis Alonso, and Jian-Ping Xiong
- Subjects
0301 basic medicine ,Male ,Platelet Aggregation ,General Physics and Astronomy ,030204 cardiovascular system & hematology ,Pharmacology ,Mice ,0302 clinical medicine ,Medicine ,Platelet ,Gene Knock-In Techniques ,lcsh:Science ,media_common ,Multidisciplinary ,biology ,Recombinant peptide therapy ,Drug discovery ,Tirofiban ,Thrombosis ,Healthy Volunteers ,3. Good health ,Structural biology ,medicine.drug ,Drug ,Platelet Function Tests ,Science ,media_common.quotation_subject ,Integrin ,Hemorrhage ,Mice, Transgenic ,Clot retraction ,Platelet Glycoprotein GPIIb-IIIa Complex ,Biologics ,Partial agonist ,General Biochemistry, Genetics and Molecular Biology ,Article ,03 medical and health sciences ,Structure-Activity Relationship ,von Willebrand Factor ,Animals ,Humans ,Blood Coagulation ,X-ray crystallography ,business.industry ,General Chemistry ,medicine.disease ,Platelet Activation ,Disease Models, Animal ,030104 developmental biology ,Hemostasis ,Drug Design ,biology.protein ,lcsh:Q ,business ,K562 Cells ,Peptides ,Platelet Aggregation Inhibitors - Abstract
A prevailing dogma is that inhibition of vascular thrombosis by antagonizing platelet integrin αIIbβ3 cannot be achieved without compromising hemostasis, thus causing serious bleeding and increased morbidity and mortality. It is speculated that these adverse outcomes result from drug-induced activating conformational changes in αIIbβ3 but direct proof is lacking. Here, we report the structure-guided design of peptide Hr10 and a modified form of the partial agonist drug tirofiban that act as “pure” antagonists of αIIbβ3, i.e., they no longer induce the conformational changes in αIIbβ3. Both agents inhibit human platelet aggregation but preserve clot retraction. Hr10 and modified tirofiban are as effective as partial agonist drugs in inhibiting vascular thrombosis in humanized mice, but neither causes serious bleeding, establishing a causal link between partial agonism and impaired hemostasis. Pure orthosteric inhibitors of αIIbβ3 may thus provide safer alternatives for human therapy, and valuable tools to probe structure–activity relationships in integrins., Current inhibitors of platelet integrin αIIbβ3 cause excessive bleeding, which limited their clinical use in cardiac patients. Here the authors design pure orthosteric αIIbβ3 inhibitors that prevent platelet aggregation and thrombosis without causing bleeding in humanized mouse models of thrombosis
- Published
- 2020
- Full Text
- View/download PDF